A resource for physicians and patients about thrombosis.
ThrombosisManagement is a Continuing Medical Education (CME) programme on theheart.org with regular updates.
A quarterly review journal, in print and online, which identifies and highlights the important developments in all aspects of clinical and surgical orthopaedics.
A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles.
Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding.
Extended thromboprophylaxis with rivaroxaban was significantly more effective than short-term enoxaparin plus placebo for the prevention of venous thromboembolism, including symptomatic events, in patients undergoing total hip arthroplasty.
Xarelto Product Information in all official languages of the European Union provided by the European Medicines Agency